Arcus Biosciences Inc (NYSE:RCUS)
$ 15.27 -0.56 (-3.54%) Market Cap: 1.40 Bil Enterprise Value: 417.63 Mil PE Ratio: 0 PB Ratio: 2.47 GF Score: 79/100

Arcus Biosciences Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 07:50PM GMT
Release Date Price: $29.64 (+0.24%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Arcus Biosciences with us. We have Terry Rosen, CEO; Juan Jaen, President; and Bill Grossman, Chief Medical Officer.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And with that, I'll throw out our first question here on the recent collaboration. So you recently announced a 10-year collaboration with Gilead. Can you just recap for us the thinking behind this partnership and the strategic decision to choose Gilead versus more established pharma players within the I-O field itself, and then walk us through this agreement and what it means for Arcus?

Terry J. Rosen
Arcus Biosciences, Inc. - Co-Founder, Chairman & CEO

Sure. So first of all, thank you, Salveen, for including in this -- us in this. We appreciate that. And to all those who are on the line, thank you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot